Please provide your email address to receive an email when new articles are posted on . Extended adjuvant endocrine therapy after 5 years of tamoxifen with either an aromatase inhibitor or tamoxifen ...

At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

Postmenopausal women with hormone receptor-positive (HR+) breast cancer who develop arthralgia and/or myalgia (A/M) while being treated with anastrozole may want to consider a switch to letrozole ...

Primary endocrine therapy (PET) with aromatase inhibitors (AIs) is an option in elderly patients unfit for or unwilling to undergo surgery. We studied the outcome of patients treated with letrozole as ...

Study Design. This trial randomized 5187 postmenopausal women with primary breast cancer that was predominantly ER+ and/or PgR+ to receive either letrozole or placebo for 5 years; receptor status was ...

The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 ...

SAN ANTONIO — Extended adjuvant endocrine therapy with letrozole improved DFS compared with placebo among postmenopausal women with hormone receptor-positive breast cancer who completed previous ...

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Postmenopausal women with ER-positive primary BC and tumors greater than ...

In the middle of this year's Breast Cancer Awareness Month, women with breast cancer have heard some encouraging news about treatment. A hormonal therapy called letrozole, also known as Femara, may ...

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy. The results of a ...

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy The oncology community faced the ...

For women with unexplained infertility, treatment with letrozole (Femara), an aromatase inhibitor, for ovarian stimulation yielded lower rates of multiple gestation, but also lower rates of clinical ...